Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Innovative Medical |
---|---|
Information provided by: | Innovative Medical |
ClinicalTrials.gov Identifier: | NCT00347841 |
To evaluate the IOP-lowering efficacy of bimatoprost 0.03% in patients found to be low-responders to latanoprost therapy.
Condition | Intervention | Phase |
---|---|---|
Glaucoma |
Drug: Bimatoprost 0.03%, Latanoprost |
Phase IV |
Study Type: | Interventional |
Study Design: | Non-Randomized, Open Label, Active Control, Single Group Assignment |
Official Title: | Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
· Male or female > 18 years of age
Exclusion Criteria:
· Known contraindication to bimatoprost or any component of any study medication
Study ID Numbers: | 5178 |
Study First Received: | June 30, 2006 |
Last Updated: | May 30, 2007 |
ClinicalTrials.gov Identifier: | NCT00347841 History of Changes |
Health Authority: | United States: Institutional Review Board |
Bimatoprost Glaucoma Eye Diseases Cardiovascular Agents |
Antihypertensive Agents Latanoprost Hypertension Ocular Hypertension |
Bimatoprost Glaucoma Therapeutic Uses Eye Diseases Cardiovascular Agents |
Antihypertensive Agents Latanoprost Pharmacologic Actions Ocular Hypertension |